Inhibition of LDHA leads to decreased ATP, reduced AKT phosphorylation, and enhanced chemotherapy sensitivity to LBP in A549 and NCL-H1975 cells. by Siyu Yuan (7425719)

Subjects:

Data Sheet 1_Increased rate of multidrug-resistant gram-negative bacterial infections in hospitalized immunocompromised pediatric patients.docx by Sarah Khafaja (8829719)

“…Introduction<p>Multidrug resistant Gram-negative bacterial infections are considered a major public health threat. …”

Overexpression of miR-1247-3p promoted apoptosis and inhibited resistance in drug-resistant cells. by Dequan Wang (6007007)

Subjects:

Analysis of Significantly Different ARGs and Resistance Mechanisms. by Xu Jia (187142)

Subjects:

miR-1247-3p was downregulated in CRC resistant cells. by Dequan Wang (6007007)

Subjects:

Supplementing NAD+ counters the effects of Oxamate on metabolism and chemotherapy sensitivity. by Siyu Yuan (7425719)

Subjects:

<i>In vivo</i> treatment decreases bacterial burden and colonization of vital organs in a skin abscess biofilm infection model. by Robert L. Beckman I.V (22784303)

miR-1247-3p was downregulated in tissues of patients with CRC and was associated with prognosis and drug resistance. by Dequan Wang (6007007)

Subjects:

RT-qPCR Primer. by Dequan Wang (6007007)

Subjects:

CCND1 is a target gene of miR-1247-3p. by Dequan Wang (6007007)

Subjects:

miR-1247-3p plasmid. by Dequan Wang (6007007)

Subjects:

RNA-sequencing data screening for miR-1247-3p target genes. by Dequan Wang (6007007)

Subjects:

Dual luciferase primer. by Dequan Wang (6007007)

Subjects:

shCCND1 plasmid. by Dequan Wang (6007007)

Subjects:

CCND1 promoted chemoresistance in CRC. by Dequan Wang (6007007)

Subjects:

Effect of miR-1247-3p on survival in colorectal cancer patients. by Dequan Wang (6007007)

Subjects:

S1 Raw images - by Dequan Wang (6007007)

Subjects:

Introduction to the dataset. by Dequan Wang (6007007)

Subjects:

Downregulation of miR-1247-3p inhibited apoptosis and reduced chemosensitivity in cells. by Dequan Wang (6007007)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)